Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases
NCT ID: NCT03128463
Last Updated: 2017-04-25
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Total Enrollment
5000 participants
Study Classification
OBSERVATIONAL
Study Start Date
2017-02-28
Study Completion Date
2018-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Macular neovascular diseases including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. can cause severe vision loss. It has become the focus of World Health Organization's blindness- prevention cause. A new anti-VEGF drug conbercept has been approved and showed good efficacy and safety in clinical trials. But the exact therapeutic regimen and the efficacy in the real world still needs to be further studied, the reasons are as follows:
1. The efficacy and safety data of conbercept are collected from rigorous random controlled trials (RCT) , it can not fully reflect the clinical application of conbercept in the real world . Therefore, the knowledge of the therapeutic regimen, safety and efficacy of conbercept is still limited.
2. Conbercept has been approved for wet-AMD only, but in clinical practice, some doctors applied other "off-label use" of conbercept. These "off-label use" has become a common phenomenon all over the world for the instruction book of drugs usually lag behind scientific researches. There is no specific law or regulatory document of drug off-label use in China until now.
3. Anti-VEGF drugs are expensive and often require multiple treatments, and some patients have poor or even no response to the drugs. This resulted enormous waste of medical resources. So, how to accurately find out those patients who have good response, how to develop individualized therapeutic regimen, and the response of patients in the real world need to be urgently investigated in the aspect of pharmacogenomics, and pharmacometabolomics.
Therefore, the investigators plan to carry out real-world researches of conbercept on treating macular neovascular diseases has significance and urgency.
The investigators intended to conduct a nationwide, non-intrusive, prospective, observational, and multicenter registration study to investigate the efficacy of conbercept in the real-world. And this study will explore the pharmacogenomics and pharmacometabolomics of conbercept, relationships of phenotype and the effectiveness of the drug, optimize the therapeutic regimen, then reduce the financial burden of patients and save the limited medical resources to achieve the purpose of accurate treatment.
For three unanswered questions raised in the background, the researchers carried out the following purposes:
1. Investigate the safety and efficacy of conbercept in treating neovascular macular disease in the real world.
2. Find out whether the "off-label use" of conbercept on PCV and PM have good efficacy.
3. Explore the pharmacogenomics and pharmacometabolomics of conbercept through large-sample registration study.
1. The efficacy and safety data of conbercept are collected from rigorous random controlled trials (RCT) , it can not fully reflect the clinical application of conbercept in the real world . Therefore, the knowledge of the therapeutic regimen, safety and efficacy of conbercept is still limited.
2. Conbercept has been approved for wet-AMD only, but in clinical practice, some doctors applied other "off-label use" of conbercept. These "off-label use" has become a common phenomenon all over the world for the instruction book of drugs usually lag behind scientific researches. There is no specific law or regulatory document of drug off-label use in China until now.
3. Anti-VEGF drugs are expensive and often require multiple treatments, and some patients have poor or even no response to the drugs. This resulted enormous waste of medical resources. So, how to accurately find out those patients who have good response, how to develop individualized therapeutic regimen, and the response of patients in the real world need to be urgently investigated in the aspect of pharmacogenomics, and pharmacometabolomics.
Therefore, the investigators plan to carry out real-world researches of conbercept on treating macular neovascular diseases has significance and urgency.
The investigators intended to conduct a nationwide, non-intrusive, prospective, observational, and multicenter registration study to investigate the efficacy of conbercept in the real-world. And this study will explore the pharmacogenomics and pharmacometabolomics of conbercept, relationships of phenotype and the effectiveness of the drug, optimize the therapeutic regimen, then reduce the financial burden of patients and save the limited medical resources to achieve the purpose of accurate treatment.
For three unanswered questions raised in the background, the researchers carried out the following purposes:
1. Investigate the safety and efficacy of conbercept in treating neovascular macular disease in the real world.
2. Find out whether the "off-label use" of conbercept on PCV and PM have good efficacy.
3. Explore the pharmacogenomics and pharmacometabolomics of conbercept through large-sample registration study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
NCT03869684
Age-related Macular Degeneration
TERMINATED
PHASE2
VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)
NCT01249664
Myopia, Pathological
COMPLETED
PHASE3
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
NCT02802657
Age-related Macular Degeneration
UNKNOWN
PHASE4
Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
NCT07133438
Retinal Vein Occlusion (RVO)
NOT_YET_RECRUITING
PHASE4
Treatment of Age-related Macular Degeneration by Fetal Retinal Pigment Epithelial Cells Transplantation
NCT02868424
Age Related Macular Degeneration
Macular Degeneration
AMD
UNKNOWN
EARLY_PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Research Background
Macular neovascular disease, is a group of diseases with subfoveal choroidal neovascularization, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. Due to the high permeability of immature blood vessel wall, consequent bleeding, and scarring，macular neovascularization often leads to severe vision loss. It has become the focus of World Health Organization's blindness- prevention cause \[1\]. Currently, the vascular endothelial growth factor (VEGF) has been widely recognized as an important promoter for neovascularization. And a series of large-scale clinical studies revealed that anti- VEGF drug is the only effective way for macular neovascular disease \[2\], Anti-VEGF drug has been awarded as one of the top ten scientific and technological progress by Nature magazine.
Conbercept is an anti-VEGF drug developed independently by Chinese researchers in recent years, it competitively prevents the binding of VEGF to its receptor and inhibits the downstream pathway activation, and has a higher binding affinity to VEGFA than other widely used anti-VEGF drugs. Many multicenter double blind random controlled study showed that conbercept has good efficacy and safety in treating macular neovascular diseases. In 2013, conbercept has been approved by the State Food and Drug Regulatory Administration of China and now has been widely used and recognized.
Clinical trial results showed that the conbercept has good efficacy and safety in treating macular neovascular diseases \[3\], but the exact therapeutic regimen and the efficacy in the real world still needs to be further studied, the reasons are as follows:
1. The efficacy and safety data of conbercept are collected from rigorous random controlled trials (RCT), it cannot fully reflect the clinical application of conbercept in the real world. Therefore, the knowledge of the therapeutic regimen, safety and efficacy of conbercept is still limited.
2. Conbercept has been approved for wet-AMD only, but in clinical practice, some doctors applied other "off-label use" of conbercept. These "off-label use" has become a common phenomenon all over the world for the instruction book of drugs usually lag behind scientific researches. There is no specific law or regulatory document of drug off-label use in China until now.
3. Anti-VEGF drugs are expensive and often require multiple treatments, besides, some patients have poor or even no response to the drugs. This resulted enormous waste of medical resources. So, how to accurately find out those patients who have good response, how to develop individualized therapeutic regimen, and the response of patients in the real world need to be urgently investigated in the aspect of pharmacogenomics, and pharmacometabolomics.
Therefore, the investigators plan to carry out real-world researches of conbercept on treating macular neovascular diseases has significance and urgency.
Scientific assumptions
The investigators intended to conduct a nationwide， non-intrusive, prospective, observational, and multicenter registration study to investigate the efficacy of conbercept in the real-world. And this study will explore the pharmacogenomics and pharmacometabolomics of conbercept, relationships of phenotype and the effectiveness of the drug, optimize the therapeutic regimen, then reduce the financial burden of patients and save the limited medical resources to achieve the purpose of accurate treatment.
For three unanswered questions raised in the background, the researchers carried out the following purposes:
1. Investigate the safety and efficacy of conbercept in treating neovascular macular disease in the real world.
2. Find out whether the "off-label use" of conbercept on PCV and PM have good efficacy.
3. Explore the pharmacogenomics and pharmacometabolomics of conbercept through large-sample registration study.
Research Plan
Program schedule: Total 2 years (1 year on enrollment, 1-year on observation) Start time: February of 2017 (FPFV, First Time Patient First Visit) End time: December of 2018 (LPLV, the last time Last Patient Last Visit) Clinical study report (CSR): December of 2018; Publish: June of 2019
This is an observational study, the investigators aim to observe and collect 5000 patients from forty nationwide ophthalmic centers that receive ocular injections of conbercept to treat macular neovascular diseases during December 2016- November 2017. And the follow-up observation last for one year. The investigators do not interfere patients' treatment plan during the entire research.
Registration time:
V1: baseline (enrollment period), V2: 1month after treatment, V3: 3 months, V4: 6 months, V5: 12 months.
Data collection and transfer:
In each visit, patients' demographic information, vital sign, history of systematic diseases, concomitant medication, eye disease history, eye examinations record, safety information and blood samples are collected. Clinical data and fundus imaging data collected by forty clinical centers will be uploaded to Shanghai Jiaotong University Ophthalmic Reading Center database then be analyzed and evaluated together.
Statistics Program: Statistical general principles:
All data will undergo descriptive statistics and statistical tests，analysis will be based on baseline and follow-up data.
Sample size:
Plan to enroll 5,000 patients by 40 hospitals. The amount will depend on the registration capacity and follow-up rate.
Safety: observe the number of cases and the percentage of adverse events and severe adverse events of conbercept in real world.
Possible bias and solutions:
Patients lost to follow (such as patients from other places, can not undergo regular local follow up): Solution 1, enroll in local patients or patients who plan to have regular and long-term follow-up in our hospital; 2, Follow up and register by telephone.
Poor patient compliance: offer some compensation for patients' transport costs.
Patients who cannot afford the drugs due to economic conditions: pharmaceutical has policies on drug donation for this population.
Quality control and Management:
Object Data Management: Ensure that all enrolled patients have signed informed consent. Each visit information should be timely, accurately and completely recorded and entered into the electronic case report form (CRF). The electronic CRF should be consistent with the original medical records. All adverse events, concomitant medications should be documented, serious adverse events should be reported to the relevant authorities within 24 hours.
Follow-up management: follow-up should be conducted according to required time point and rules. Researchers should try to find out the reasons of losing visit and avoid them. If patients failed to come to clinic, then the researchers should make a phone call follow up. If patients refused to continue participating in the study for some concerns, they should be interpreted by reasonable encourages to continue cooperation.
Macular neovascular disease, is a group of diseases with subfoveal choroidal neovascularization, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), pathological myopia (PM) and etc. Due to the high permeability of immature blood vessel wall, consequent bleeding, and scarring，macular neovascularization often leads to severe vision loss. It has become the focus of World Health Organization's blindness- prevention cause \[1\]. Currently, the vascular endothelial growth factor (VEGF) has been widely recognized as an important promoter for neovascularization. And a series of large-scale clinical studies revealed that anti- VEGF drug is the only effective way for macular neovascular disease \[2\], Anti-VEGF drug has been awarded as one of the top ten scientific and technological progress by Nature magazine.
Conbercept is an anti-VEGF drug developed independently by Chinese researchers in recent years, it competitively prevents the binding of VEGF to its receptor and inhibits the downstream pathway activation, and has a higher binding affinity to VEGFA than other widely used anti-VEGF drugs. Many multicenter double blind random controlled study showed that conbercept has good efficacy and safety in treating macular neovascular diseases. In 2013, conbercept has been approved by the State Food and Drug Regulatory Administration of China and now has been widely used and recognized.
Clinical trial results showed that the conbercept has good efficacy and safety in treating macular neovascular diseases \[3\], but the exact therapeutic regimen and the efficacy in the real world still needs to be further studied, the reasons are as follows:
1. The efficacy and safety data of conbercept are collected from rigorous random controlled trials (RCT), it cannot fully reflect the clinical application of conbercept in the real world. Therefore, the knowledge of the therapeutic regimen, safety and efficacy of conbercept is still limited.
2. Conbercept has been approved for wet-AMD only, but in clinical practice, some doctors applied other "off-label use" of conbercept. These "off-label use" has become a common phenomenon all over the world for the instruction book of drugs usually lag behind scientific researches. There is no specific law or regulatory document of drug off-label use in China until now.
3. Anti-VEGF drugs are expensive and often require multiple treatments, besides, some patients have poor or even no response to the drugs. This resulted enormous waste of medical resources. So, how to accurately find out those patients who have good response, how to develop individualized therapeutic regimen, and the response of patients in the real world need to be urgently investigated in the aspect of pharmacogenomics, and pharmacometabolomics.
Therefore, the investigators plan to carry out real-world researches of conbercept on treating macular neovascular diseases has significance and urgency.
Scientific assumptions
The investigators intended to conduct a nationwide， non-intrusive, prospective, observational, and multicenter registration study to investigate the efficacy of conbercept in the real-world. And this study will explore the pharmacogenomics and pharmacometabolomics of conbercept, relationships of phenotype and the effectiveness of the drug, optimize the therapeutic regimen, then reduce the financial burden of patients and save the limited medical resources to achieve the purpose of accurate treatment.
For three unanswered questions raised in the background, the researchers carried out the following purposes:
1. Investigate the safety and efficacy of conbercept in treating neovascular macular disease in the real world.
2. Find out whether the "off-label use" of conbercept on PCV and PM have good efficacy.
3. Explore the pharmacogenomics and pharmacometabolomics of conbercept through large-sample registration study.
Research Plan
Program schedule: Total 2 years (1 year on enrollment, 1-year on observation) Start time: February of 2017 (FPFV, First Time Patient First Visit) End time: December of 2018 (LPLV, the last time Last Patient Last Visit) Clinical study report (CSR): December of 2018; Publish: June of 2019
This is an observational study, the investigators aim to observe and collect 5000 patients from forty nationwide ophthalmic centers that receive ocular injections of conbercept to treat macular neovascular diseases during December 2016- November 2017. And the follow-up observation last for one year. The investigators do not interfere patients' treatment plan during the entire research.
Registration time:
V1: baseline (enrollment period), V2: 1month after treatment, V3: 3 months, V4: 6 months, V5: 12 months.
Data collection and transfer:
In each visit, patients' demographic information, vital sign, history of systematic diseases, concomitant medication, eye disease history, eye examinations record, safety information and blood samples are collected. Clinical data and fundus imaging data collected by forty clinical centers will be uploaded to Shanghai Jiaotong University Ophthalmic Reading Center database then be analyzed and evaluated together.
Statistics Program: Statistical general principles:
All data will undergo descriptive statistics and statistical tests，analysis will be based on baseline and follow-up data.
Sample size:
Plan to enroll 5,000 patients by 40 hospitals. The amount will depend on the registration capacity and follow-up rate.
Safety: observe the number of cases and the percentage of adverse events and severe adverse events of conbercept in real world.
Possible bias and solutions:
Patients lost to follow (such as patients from other places, can not undergo regular local follow up): Solution 1, enroll in local patients or patients who plan to have regular and long-term follow-up in our hospital; 2, Follow up and register by telephone.
Poor patient compliance: offer some compensation for patients' transport costs.
Patients who cannot afford the drugs due to economic conditions: pharmaceutical has policies on drug donation for this population.
Quality control and Management:
Object Data Management: Ensure that all enrolled patients have signed informed consent. Each visit information should be timely, accurately and completely recorded and entered into the electronic case report form (CRF). The electronic CRF should be consistent with the original medical records. All adverse events, concomitant medications should be documented, serious adverse events should be reported to the relevant authorities within 24 hours.
Follow-up management: follow-up should be conducted according to required time point and rules. Researchers should try to find out the reasons of losing visit and avoid them. If patients failed to come to clinic, then the researchers should make a phone call follow up. If patients refused to continue participating in the study for some concerns, they should be interpreted by reasonable encourages to continue cooperation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Age-Related Macular Degeneration
Polypoidal Choroidal Vasculopathy
Pathological Myopia
Conbercept
Pharmacogenomic
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
significantly effective group
visual improvement ≥15 letters in Early Treatment Diabetic Retinopathy Study (EDTRS) table after intravitreal injection of conbercept
Intravitreal injection of conbercept
Intervention Type
DRUG
We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
effective group
visual improvement ≥5 letters and \<15 letters in EDTRS table after intravitreal injection of conbercept
Intravitreal injection of conbercept
Intervention Type
DRUG
We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
invalid group
visual improvement \<5 letters and visual reduction\<5 letters in EDTRS table after intravitreal injection of Combercept
Intravitreal injection of conbercept
Intervention Type
DRUG
We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
deterioration group
visual reduction≥5 letters in EDTRS table after intravitreal injection of conbercept
Intravitreal injection of conbercept
Intervention Type
DRUG
We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Intravitreal injection of conbercept
We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Signed informed consent
2. Patients were diagnosed with macular neovascular disease (wet age- related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV)and choroidal neovascularization secondary to pathological myopia (PM) ), no gender requirement, age ≥ 18years
3. Patients plan to receive intravitreal injection of conbercept;
4. Patients should be resident in this region or who plans a long-term follow- up in the clinical center.
2. Patients were diagnosed with macular neovascular disease (wet age- related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV)and choroidal neovascularization secondary to pathological myopia (PM) ), no gender requirement, age ≥ 18years
3. Patients plan to receive intravitreal injection of conbercept;
4. Patients should be resident in this region or who plans a long-term follow- up in the clinical center.
Exclusion Criteria
1. Participate in other intervention therapy at the same time
2. Received anti- VEGF treatment (including intravitreal injection or systematic application) within three months prior to enrollment .
2. Received anti- VEGF treatment (including intravitreal injection or systematic application) within three months prior to enrollment .
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Zhongshan Ophthalmic Center, Sun Yat-sen University
OTHER
Sponsor Role
collaborator
Peking University
OTHER
Sponsor Role
collaborator
Air Force Military Medical University, China
OTHER
Sponsor Role
collaborator
Tianjin Medical University
OTHER
Sponsor Role
collaborator
Xun Xu
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Xun Xu
Professor
Responsibility Role
SPONSOR_INVESTIGATOR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Shi, Shanghai Municipality, China
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
China
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Wong CW, Yanagi Y, Lee WK, Ogura Y, Yeo I, Wong TY, Cheung CMG. Age-related macular degeneration and polypoidal choroidal vasculopathy in Asians. Prog Retin Eye Res. 2016 Jul;53:107-139. doi: 10.1016/j.preteyeres.2016.04.002. Epub 2016 Apr 14.
Reference Type
BACKGROUND
CATT Research Group; Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
Reference Type
BACKGROUND
Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, Zhang F, Zhang J, Tang L, Wu Q, Luo D, Ke X; AURORA Study Group. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology. 2014 Sep;121(9):1740-7. doi: 10.1016/j.ophtha.2014.03.026. Epub 2014 May 1.
Reference Type
BACKGROUND
Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, Harding S, Johnston RL, Kelly SP, Lotery A, Mahmood S, Menon G, Sivaprasad S, Talks J, Tufail A, Yang Y. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015 Jun;29(6):721-31. doi: 10.1038/eye.2015.48. Epub 2015 Apr 17.
Reference Type
BACKGROUND
Qu Y, Liu Y, Fang J, Chen C, Cheng L, Xu X, Jin J, Chen X, Niu T, Wang H, Xing X, Shi X, Shen Y, Liu K. Dysregulated serum lipid profiles in neovascular age-related macular degeneration revealed by UPLC-MS/MS lipidomics. Lipids Health Dis. 2025 Sep 29;24(1):302. doi: 10.1186/s12944-025-02735-y.
Reference Type
DERIVED
Jing J, Yinchen S, Xia C, Jing W, Chong C, Xun X, Hengye H, Kun L. Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study. BMC Ophthalmol. 2018 Jul 24;18(1):181. doi: 10.1186/s12886-018-0812-4.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016YFC0904800
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration
NCT04270669
COMPLETED
PHASE1/PHASE2
RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD)
NCT04832724
COMPLETED
PHASE2
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT05986864
RECRUITING
PHASE1/PHASE2
Efficacy and Safety of Intravitreal Conbercept With Modified Treat-and-Extend Regimens in Exudative AMD
NCT05539235
UNKNOWN
PHASE2/PHASE3
A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT06213038
RECRUITING
PHASE1
Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization.
NCT07329686
RECRUITING
PHASE1/PHASE2
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
NCT05099094
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)
NCT04468997
UNKNOWN
PHASE1
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
NCT06196840
ACTIVE_NOT_RECRUITING
PHASE2
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
NCT01003691
COMPLETED
PHASE1
An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)
NCT02098720
UNKNOWN
PHASE2
Anti-VEGF Therapy for Subfoveal Hemorrhage in Patients With Neovascular Age-Related Macular Degeneration
NCT03699618
TERMINATED
A Study of EXG102-031 in Participants With wAMD
NCT06183814
RECRUITING
PHASE1/PHASE2
CM082 in Patients With Myopic Choroidal Neovascularization (CNV)
NCT04222842
SUSPENDED
PHASE1
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
NCT01245387
COMPLETED
Cohort Study of the Clinical Course of Macular Diseases in Japanese
NCT02081339
UNKNOWN
A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD
NCT05297292
UNKNOWN
PHASE2/PHASE3
Impact of Non-Exudative Type 1 MNV on AMD Progression
NCT06125977
ACTIVE_NOT_RECRUITING
Safety and Tolerability of Oral CM082 in Patients With wAMD
NCT03710863
UNKNOWN
PHASE2
VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
NCT01482910
COMPLETED
PHASE3
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
NCT02713204
COMPLETED
PHASE2
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
NCT00150202
COMPLETED
PHASE3
Eyes That Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion
NCT04836143
COMPLETED
Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration
NCT07088445
NOT_YET_RECRUITING
Phase II/III Study of Anti-VEGF in Neovascular AMD
NCT00021736
COMPLETED
PHASE2/PHASE3